Bioverativ
Inc. (BIVV ) today announced it will report fourth quarter
and year-end 2017 financial results on Tuesday, February 13, 2018, after
the market closes. The press release will be available in the "Investor
Relations" section of the companys website at investors.bioverativ.com.

On Wednesday, February 14, 2018, at 8:00 a.m. EST, the company will host
a live webcast with Bioverativ management. To access the live webcast,
please visit Bioverativs Investors page at investors.bioverativ.com.
An archived version of the webcast will be available following the
presentation.

About Bioverativ

Bioverativ (BIVV ) is a global biopharmaceutical company
dedicated to transforming the lives of people with hemophilia and other
rare blood disorders through world-class research, development and
commercialization of innovative therapies. Launched in 2017 following
separation from Biogen Inc., Bioverativ builds upon a strong heritage of
scientific innovation and is committed to actively working with the
blood disorders community. The companys mission is to create progress
for patients where they need it most and its hemophilia therapies when
launched represented the first major advancements in hemophilia
treatment in more than two decades. For more information, visit www.bioverativ.com
or follow @bioverativ
on Twitter.